Sarah Katz Caffeine Safety Act
- Sponsor
- Rep. Menendez, Robert [D-NJ-8]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Mar 31, 2025
Bottom line
The Sarah Katz Caffeine Safety Act aims to enhance consumer safety and informed choice regarding caffeine consumption through comprehensive labeling, scientific review, and public education.
What it actually does
This bill mandates new labeling requirements for caffeine content in chain restaurants and packaged foods/dietary supplements. It requires chain restaurants to label menu items with 'High caffeine' if they contain at least 150mg of added caffeine and disclose total caffeine. Packaged foods and supplements with over 10mg of caffeine must disclose the amount, source (natural or additive), and a daily recommended limit advisory. Additionally, the bill directs the FDA and NIH to conduct reviews on caffeine safety, especially for vulnerable populations, and establishes a public education campaign and a GAO study on caffeine marketing.
Proponents argue
Supporters argue that the bill is a crucial step to protect public health by providing consumers with clear, actionable information about caffeine content, especially in an era of increasingly potent caffeinated products. They contend it will help prevent accidental overconsumption, particularly among vulnerable populations like children and individuals with underlying health conditions, and ensure that regulatory frameworks are updated with current scientific understanding.
Opponents contend
Critics may argue that the bill imposes significant and potentially costly regulatory burdens on restaurants and food manufacturers, which could lead to increased prices or reduced product variety. They might also contend that consumers are already generally aware of caffeine's effects and sources, and that extensive new labeling could lead to information overload without a substantial improvement in public health outcomes.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its provisions within a reasonable timeframe.
Section 2(a)
Enhanced Caffeine Labeling for Chain Restaurants
This provision amends the Federal Food, Drug, and Cosmetic Act to require chain restaurants (those with 20 or more locations) to disclose specific caffeine information. For standard and temporary menu items containing added caffeine and at least 150 milligrams of total caffeine per serving, the menu and menu board must display a 'High caffeine' statement or similar symbol. Additionally, the exact number of milligrams of caffeine in the item must be disclosed.
Supporters argue
Proponents argue that this provision is essential for consumer safety, especially given the variability of caffeine content in restaurant beverages and food items. It empowers individuals to make informed choices, preventing accidental overconsumption and protecting those sensitive to caffeine.
Critics contend
Opponents may contend that these requirements impose significant operational and financial burdens on chain restaurants, potentially leading to increased costs for consumers or reduced menu flexibility. They might also argue that many consumers are already aware of high-caffeine items.
Tradeoffs
The provision balances the public health benefit of informed consumer choice against the compliance costs and logistical challenges faced by the restaurant industry.
Section 2(b)
Caffeine Labeling for Packaged Foods and Dietary Supplements
This section mandates new labeling requirements for packaged foods and dietary supplements that contain more than 10 milligrams of caffeine. The label must clearly state the total number of milligrams of caffeine, indicate whether the caffeine is naturally occurring or an additive, and include an advisory statement about the daily recommended limit of 400 milligrams for healthy adults (or another limit determined by the Secretary).
Section 3(a)
FDA Review of Caffeine Safety and GRAS Status
This section directs the Commissioner of Food and Drugs (FDA) to conduct a comprehensive review of the safety of caffeine and other stimulants in food and dietary supplements. The review must specifically assess whether caffeine should continue to be considered 'Generally Recognized As Safe' (GRAS) for healthy populations, evaluate the safety of added stimulants, and consider appropriate thresholds for caffeine content. The FDA is required to submit a report detailing its findings to Congress within six months.
Section 3(b)
NIH Review of Caffeine Effects on Vulnerable Populations
This provision mandates that the Director of the National Institutes of Health (NIH) conduct or support a review of the effects of caffeine and other stimulants on specific vulnerable populations. These populations include children and adolescents, individuals with underlying heart conditions, pregnant and breast-feeding women, individuals with seizure disorders, those with mental health conditions worsened by stimulants, and caffeine-sensitive individuals. A report on these findings must be submitted to Congress within six months.
Section 4
Public Education Campaign on Caffeine Safety
This section directs the Secretary of Health and Human Services, through the FDA Commissioner and in consultation with the CDC Director, to conduct a public education campaign on the safe consumption of caffeine and caffeinated products. The campaign is specifically tasked with addressing the dangers of overconsumption, health impacts on vulnerable populations, marketing practices targeting children and adolescents, the effects of other substances like guarana and taurine, and general safe consumption practices.
Section 5
GAO Study on Caffeinated Beverage Marketing
This section directs the Comptroller General of the United States (GAO) to conduct a study on the marketing of caffeinated beverages across various platforms, including restaurants, stores, and online (social media and influencers). The study will specifically focus on identifying misleading marketing practices and how these beverages are targeted at children and teens. A report detailing the study's results and offering legislative or administrative recommendations is due to Congress within 180 days.
These subsections contain technical conforming amendments to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343(q)(5)). They involve redesignating existing subclauses and updating internal cross-references to ensure that the newly inserted caffeine labeling requirements integrate correctly into the broader statutory framework.
Section 2(a)(1)(B)(i), (C) and Section 2(a)(2)
Why it matters:This is standard legislative practice. When new provisions are inserted into an existing, complex statute, technical amendments are necessary to maintain the internal consistency and correct referencing of the law. It ensures that all parts of the act correctly point to the intended sections.
Case for: Ensures the new caffeine labeling requirements are legally sound and enforceable by correctly integrating them into the existing Federal Food, Drug, and Cosmetic Act. Without these technical adjustments, there could be ambiguities or conflicts with other parts of the law.
Case against: There is no substantive case against technical conforming amendments; they are essential for the legal clarity and functionality of the bill's primary policy changes.
Estimated impact: The impact is primarily legal and administrative, ensuring the smooth implementation and enforcement of the bill's core provisions. It clarifies the regulatory scope for the FDA and regulated entities.